The impact of the COVID-19 pandemic on adult bronchiectasis patients and the relationship between clinical parameters and bronchiectasis severity.

IF 3.3 4区医学 Q1 Medicine European review for medical and pharmacological sciences Pub Date : 2024-07-01 DOI:10.26355/eurrev_202407_36528

S Gul, M A Uysal, H Abalı, A Yeter, E S Akalın Karaca, N Alagoz, D Bilici, E Y Ozgun Niksarlıoglu

{"title":"The impact of the COVID-19 pandemic on adult bronchiectasis patients and the relationship between clinical parameters and bronchiectasis severity.","authors":"S Gul, M A Uysal, H Abalı, A Yeter, E S Akalın Karaca, N Alagoz, D Bilici, E Y Ozgun Niksarlıoglu","doi":"10.26355/eurrev_202407_36528","DOIUrl":null,"url":null,"abstract":"Objective: Viral infections are an important cause of exacerbation in bronchiectasis patients. We aimed to determine the influence of the COVID-19 pandemic on adult bronchiectasis patients and whether there was a relationship between the clinical parameters and the COVID-19 infection.Patients and methods: In this retrospective observational study, 547 bronchiectasis patients were included. Demographic characteristics, vaccination status, Bronchiectasis Severity Index (BSI), FACED and Reiff scores, and clinical and laboratory parameters during COVID-19 infection were evaluated.Results: The median age was 56, and 49.2% of the patients were male. The COVID-19 infection rate was 27.6%. 431 (78.8%) patients had at least one dose of the COVID-19 vaccine. The patients were divided into two groups according to their COVID-19 infection status. Emergency admission was significantly higher in the COVID-19-infected group. There was no statistical difference with other clinical factors. The COVID-19-infected patients were divided into home treatment and hospital/intensive care unit (ICU) treatment groups. There was a statistically significant difference between the two groups regarding advanced age, male gender, presence of asthma, long-term oxygen therapy (LTOT) and non-invasive mechanic ventilator (NIMV) usage, sputum culture positivity, BSI and FACED scores, and multiple laboratory parameters (ferritin, C-reactive protein, eosinophil). In logistic regression analysis, BSI was found as a risk factor [OR 1.252 (1.077-1.456), p=0.004] and eosinophilia as a protective factor [OR 0.986 (0.973-0.999), p=0.030] for hospital/ICU admission.Conclusions: Frequent emergency visits might increase the risk of COVID-19 infection in bronchiectasis patients. BSI was found to be an independent risk factor, and blood eosinophilia could play a protective role in hospital/ICU admission for COVID-19 infection.","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"28 13","pages":"3958-3968"},"PeriodicalIF":3.3000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European review for medical and pharmacological sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.26355/eurrev_202407_36528","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Viral infections are an important cause of exacerbation in bronchiectasis patients. We aimed to determine the influence of the COVID-19 pandemic on adult bronchiectasis patients and whether there was a relationship between the clinical parameters and the COVID-19 infection.

Patients and methods: In this retrospective observational study, 547 bronchiectasis patients were included. Demographic characteristics, vaccination status, Bronchiectasis Severity Index (BSI), FACED and Reiff scores, and clinical and laboratory parameters during COVID-19 infection were evaluated.

Results: The median age was 56, and 49.2% of the patients were male. The COVID-19 infection rate was 27.6%. 431 (78.8%) patients had at least one dose of the COVID-19 vaccine. The patients were divided into two groups according to their COVID-19 infection status. Emergency admission was significantly higher in the COVID-19-infected group. There was no statistical difference with other clinical factors. The COVID-19-infected patients were divided into home treatment and hospital/intensive care unit (ICU) treatment groups. There was a statistically significant difference between the two groups regarding advanced age, male gender, presence of asthma, long-term oxygen therapy (LTOT) and non-invasive mechanic ventilator (NIMV) usage, sputum culture positivity, BSI and FACED scores, and multiple laboratory parameters (ferritin, C-reactive protein, eosinophil). In logistic regression analysis, BSI was found as a risk factor [OR 1.252 (1.077-1.456), p=0.004] and eosinophilia as a protective factor [OR 0.986 (0.973-0.999), p=0.030] for hospital/ICU admission.

Conclusions: Frequent emergency visits might increase the risk of COVID-19 infection in bronchiectasis patients. BSI was found to be an independent risk factor, and blood eosinophilia could play a protective role in hospital/ICU admission for COVID-19 infection.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

COVID-19 大流行对成年支气管扩张症患者的影响以及临床参数与支气管扩张症严重程度之间的关系。

目的：病毒感染是支气管扩张症患者病情加重的重要原因：病毒感染是支气管扩张症患者病情加重的重要原因。我们旨在确定 COVID-19 大流行对成年支气管扩张症患者的影响，以及临床参数与 COVID-19 感染之间是否存在关系：在这项回顾性观察研究中，共纳入了 547 名支气管扩张症患者。评估了人口统计学特征、疫苗接种情况、支气管扩张症严重程度指数（BSI）、FACED和Reiff评分以及COVID-19感染期间的临床和实验室指标：中位年龄为 56 岁，49.2% 的患者为男性。COVID-19 感染率为 27.6%。431名（78.8%）患者至少接种过一剂COVID-19疫苗。根据 COVID-19 感染情况，患者被分为两组。COVID-19感染组的急诊入院率明显较高。其他临床因素没有统计学差异。COVID-19 感染者被分为家庭治疗组和医院/重症监护室（ICU）治疗组。两组患者在高龄、男性、哮喘、长期氧疗（LTOT）和无创机械通气（NIMV）的使用、痰培养阳性、BSI 和 FACED 评分以及多项实验室指标（铁蛋白、C 反应蛋白、嗜酸性粒细胞）方面均存在统计学差异。在逻辑回归分析中发现，BSI 是入院/入住重症监护室的风险因素[OR 1.252 (1.077-1.456)，p=0.004]，而嗜酸性粒细胞增多是入院/入住重症监护室的保护因素[OR 0.986 (0.973-0.999)，p=0.030]：结论：频繁的急诊就医可能会增加支气管扩张患者感染 COVID-19 的风险。结论：频繁的急诊就诊可能会增加支气管扩张症患者感染 COVID-19 的风险，BSI 是一个独立的风险因素，而血液嗜酸性粒细胞增多可能对 COVID-19 感染入院/入住重症监护室起到保护作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

European review for medical and pharmacological sciences 医学-药学

CiteScore

5.30

自引率

6.10%

发文量

906

审稿时长

2-4 weeks

期刊介绍： European Review for Medical and Pharmacological Sciences, a fortnightly journal, acts as an information exchange tool on several aspects of medical and pharmacological sciences. It publishes reviews, original articles, and results from original research. The purposes of the Journal are to encourage interdisciplinary discussions and to contribute to the advancement of medicine. European Review for Medical and Pharmacological Sciences includes: -Editorials- Reviews- Original articles- Trials- Brief communications- Case reports (only if of particular interest and accompanied by a short review)